Abstract
Objective The aim was to determine the prognostic significance of CD81 expression in patients with acute myeloid leukemia (AML) and its effect on patients’ survival. Patients and methods This study was carried out on 50 patients with newly diagnosed AML. Expression of CD81 was detected by flow cytometry, and then all the patients received chemotherapy and were observed for a period of 12 months regarding clinical and laboratory findings of remission and relapse. Results Our results showed that positive expression of CD81 was detected in 30/50 (60%) patients. Clinical remission was achieved in six (12%) patients with positive expression of CD81, whereas it was achieved in 12 (24%) patients with negative CD81 expression. Relapse occurred in 19 (38%) patients with positive expression of CD81, whereas it occurred in six (12%) patients with negative CD81 expression. Death occurred in five (10%) patients with positive expression of CD81 and in two (4%) patients with negative expression of CD81. Conclusion CD81 expression has a potential role as a prognostic marker as its expression was associated with patients with high-risk AML, with higher white blood cells, higher lactate dehydrogenase, and higher blast percentage in bone marrow, and M1 and M5 FAB subtypes. Decreased overall survival and disease-free survival in patients with CD81-positive expression than in patients with CD81-negative expression was also observed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
